📰 Daniel Burkhoff News
Daniel Burkhoff News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Daniel Burkhoff. Real-time updates on events, politics, business and more.
March 28, 2024
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Expansion of U.S.
February 29, 2024
The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An internat
February 29, 2024
The complete list of late-breaking clinical science to be presented at THT 2024: Technology and Heart Failure Therapeutics is now available online. An internat
March 24, 2023
First-in-human snapshots, pilot studies, roll-in cohorts, and post-hoc analyses showcase diverse technologies, but few certainties.
February 12, 2023
Wearable causes excess fluids to be sweated out and evaporated on the skin without discomfort, using very low humidity and fast flowing air.
September 20, 2022
Puzzle Medical Devices, a provider of hemodynamic support in Heart Failure (HF), was selected as the winner of the TCT 2022 Innovation Shark Tank Competition. The award program was held during the TCT 2022 Conference on Monday, September 19, in Boston, MA.
September 20, 2022
Statistically significant mean reductions of 10.3 mmHg in 24-hour ambulatory systolic blood pressure and 11.7 mmHg in ambulatory pulse pressure after 6 months of therapy in control patients who crossed over to BackBeat CNT following completion of the randomized portion of the MODERATO II study
August 19, 2022
From 2013 to 2019, the number of cases using PVADs more than quadrupled, but uptake varied considerably around the US.
July 7, 2022
REDUCE-LAP HF II dampened some hopes for LA shunts in heart failure, but the field is learning lessons and moving forward.
April 16, 2021
April 15, 2021 For patients who have pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), treatment with levosimendan (Simdax; Tenax Therapeutics) can improve both pulmonary congestion and submaximal exercise capacity when compared with placebo, according to the results of a small study. While the phase II study missed its primary endpoint, which was a reduction in pulmonary capillary wedge pressure (PCWP) during exercise, levosimendan did reduce PCWPs across t...